Reuters logo
BRIEF-Loxo Oncology announces FDA orphan drug designation granted to larotrectinib
May 12, 2017 / 10:52 AM / 7 months ago

BRIEF-Loxo Oncology announces FDA orphan drug designation granted to larotrectinib

May 12 (Reuters) - Loxo Oncology Inc:

* Loxo Oncology announces FDA orphan drug designation granted to larotrectinib for the treatment of solid tumors with ntrk-fusion proteins Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below